Quick Answer
For the first time in decades, America's obesity rate has fallen — and GLP-1 drugs like Ozempic and Mounjaro are the reason. With 11% of US adults now on these medications, population-level results are in. India's GLP-1 market has crossed Rs 1,900 crore and generics are now available.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
For the first time in decades, the obesity rate in the United States has fallen — and public health experts are pointing to one primary cause: the rapid rise of GLP-1 medications like Ozempic, Wegovy, and Mounjaro. A report published on July 7, 2026 by U.S. News and World Report, citing data from national health surveys and the CDC, confirmed that the proportion of American adults classified as obese has declined meaningfully for the first time in a generation. In the same week, a Gallup poll found that 11 percent of American adults now take a GLP-1 medication for weight loss — up from just 3 percent in 2024. For Indian patients struggling with obesity and its many related conditions, this milestone carries a powerful message: at a population level, these medications work.
What the Numbers Actually Say
The scale of the shift in the United States is striking. In just two years, the proportion of Americans using GLP-1 drugs for weight loss nearly quadrupled. As of mid-2026, more than 1 in 10 American adults is on a GLP-1 medication. This is not a niche treatment anymore — it is one of the most rapidly adopted drug classes in medical history. And the results are now showing up not just in individual clinical trials, but in national obesity statistics. The CDC has recorded a measurable decline in the prevalence of adult obesity, a number that had risen almost without interruption for forty years.
Clinical trials had already shown that semaglutide (Ozempic, Wegovy) produces average weight loss of 13 to 15 percent of body weight, and tirzepatide (Mounjaro) up to 20 percent. But showing that these drugs work in controlled trials is one thing. Showing that widespread use actually bends the obesity curve at a national level is something far more significant — it means the drugs work in the real world, across different age groups, health conditions, dietary habits, and socioeconomic backgrounds.
Why This Is a Landmark Moment in Medicine
Obesity is not just about body weight. It is one of the most powerful drivers of type 2 diabetes, high blood pressure, heart disease, sleep apnea, fatty liver disease, certain cancers, and joint damage. Every percentage point reduction in obesity prevalence at a population level translates into millions of fewer cases of these conditions — and millions of fewer deaths, surgeries, and hospitalisations over the following decades.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Medical historians will likely look back at the period between 2023 and 2026 as the moment when obesity — long considered a largely intractable public health problem — became a medically treatable condition at scale. The United States is the first country to show this effect clearly, because it has the highest GLP-1 adoption rates in the world. But the implications extend to every country where obesity is a serious health burden — and few countries face a more urgent obesity challenge than India.
India's Obesity Crisis Is Accelerating
India is home to the second-largest population of people with type 2 diabetes in the world, with approximately 77 million adults affected. Obesity and overweight are major drivers. The prevalence of abdominal obesity in India has been rising rapidly, particularly in urban areas, and the diseases linked to it — diabetes, hypertension, fatty liver disease, sleep apnea, polycystic ovarian syndrome, and cardiovascular disease — now represent the leading causes of preventable death in India.
What makes India's situation particularly concerning is that Indian patients develop metabolic complications at lower body weights and younger ages than Western populations. A body mass index of 25 in an Indian adult carries the same metabolic risk as a BMI of 30 in a Western adult. This means that many Indian patients who would not qualify as clinically obese by international standards are already suffering from the complications of excess fat, particularly around the abdomen and organs.
The public health success now being observed in the United States — driven by GLP-1 drugs — could potentially be replicated in India if access to these medications improves. And in 2026, access is improving significantly.
India's Own GLP-1 Revolution Is Under Way
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
India's GLP-1 market has grown from Rs 127 crore in 2022 to nearly Rs 1,906 crore by May 2026 — a five-year compound annual growth rate of 237 percent, making it one of the fastest-growing pharmaceutical categories in Indian history. Tirzepatide (Mounjaro from Eli Lilly) currently holds the largest market share at 63 percent, with semaglutide holding 31 percent.
Critically, the patent on semaglutide expired in India in March 2026, opening the market to domestic generic manufacturers. Companies including Natco Pharma, Sun Pharma, and Cipla have launched generic semaglutide products, with prices starting at approximately Rs 1,290 per month for the weekly injection. This compares to Ozempic (Novo Nordisk branded semaglutide) at roughly Rs 5,600 to Rs 6,000 per month — a price reduction of more than 75 percent. For many Indian patients, this cost reduction is the difference between treatment being financially out of reach and being genuinely accessible.
Who Should Consider GLP-1 Therapy in India?
GLP-1 medications are appropriate for a broad range of Indian patients. If you have type 2 diabetes and are not achieving adequate blood sugar control on oral medications alone, your doctor may recommend semaglutide or tirzepatide as a treatment upgrade. Both drugs are approved in India for type 2 diabetes management. If you have obesity (BMI above 27.5 for Indian patients, given the lower thresholds used for our population) with at least one related condition such as high blood pressure, fatty liver, sleep apnea, or high cholesterol, you are also a candidate for GLP-1 therapy for weight management.
The evidence from the United States shows that sustained use — most patients in Gallup surveys had been on these medications for more than a year — is key to achieving the population-level benefits now being observed. These are not quick-fix drugs. They work best when used consistently, under medical supervision, alongside dietary adjustments and regular check-ins with a specialist who can monitor your progress and adjust your dose appropriately.
If you have been curious about GLP-1 therapy but unsure whether you qualify, or concerned about cost and availability in India, a consultation with a GLP-1 specialist is the right first step. The success story now unfolding in the United States offers one of the clearest signals in modern medicine: for people who need it, this treatment works.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. U.S. News and World Report — https://www.usnews.com/news/national-news/articles/2026-07-07/u-s-obesity-rate-drops-as-use-of-glp-1-weight-loss-drugs-surges 2. Gallup — https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx 3. Biospectrumindia — https://www.biospectrumindia.com/news/73/27946/glp-1-market-nears-rs-2000-cr-in-mat-may-2026-as-tirzepatide-and-semaglutide-dominate-segment-sheetal-sapale.html
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.